Clinical trials: PTSD, completed
PTSD - Post Traumatic Stress Disorder
MentalGym™ and NeuroBrave™ Guided Wearable-Assisted Physiology Regulation Training for PTSD (PRTP)
This randomized controlled trial (RCT) will evaluate the effectiveness of a digital biofeedback-based intervention ("Mental Gym®") designed to reduce Posttraumatic Stress Disorder (PTSD) symptoms and improve mental health.
- Trial name
- NCT07462312
- Testing
- Mental Gym® Biofeedback System
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- NeuroBrave ltd.
PTSD, Post Traumatic Stress Disorder
Feasibility of a Digital Therapeutic for Adults With Posttraumatic Stress Disorder (PTSD)
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
- Trial name
- NCT06868446
- Testing
- OTX-601 Digital Therapeutic - Version 1, OTX-601 Digital Therapeutic - Version 2, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oui Therapeutics, Inc.
Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia
A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares.
- Trial name
- PTSD-PoC (NCT06685965)
- Testing
- RE03
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Reconnect Labs
Stress Disorders, Post-Traumatic, Combat Disorders
NightWare Randomized Trial 02
This study will provide preliminary estimates of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with…
- Conditions
- Stress Disorders, Post-Traumatic, Combat Disorders, Ptsd, Nightmare
- Trial name
- TNT/NW (NCT04040387)
- Testing
- NightWare Therapeutic System
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- NightWare
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.
- Trial name
- MAPPUSX (NCT04714359)
- Testing
- Midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT03282123
- Testing
- Midomafetamine, Manualized therapy
- Where
- 12 sites in United States
- Volunteers
- 38 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition.
- Trial name
- P202 (NCT02421679)
- Testing
- TNX-102 SL
- Where
- 22 sites in United States
- Volunteers
- 159 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label…
- Trial name
- P306 (NCT03508700)
- Testing
- TNX-102 SL 5.6 mg
- Where
- 16 sites in United States
- Volunteers
- 93 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
PTSD, Generalized Anxiety Disorder
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms.
- Conditions
- PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT05717439
- Testing
- CAPS-5-R, Senseye DT
- Where
- 5 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
PTSD
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy.
- Trial name
- MPLONG (NCT05066282)
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 186 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
OM and Trauma Study
The primary purpose of this study is to use an unblinded, uncontrolled, 1-month interventional single group pilot study, to assess the possibility of Orgasmic Meditation practice being used as a possible intervention for PTSD.
- Trial name
- OMTP (NCT05577377)
- Testing
- Orgasmic Meditation
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institute of OM Foundation
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD
The goal of PROSPER-C is to study effectiveness of ImRs compared to integrated SFT-ImRs in treatment-seeking, adult patients with comorbid PTSD and Cluster C Personality Disorder (CPD).
- Conditions
- Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder, Dependent Personality Disorder, Obsessive Compulsive Personality Disorder
- Trial name
- PROSPER-C (NCT03833531)
- Testing
- ImRS, SFT
- Where
- Netherlands
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Arkin
PTSD
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.
- Trial name
- NCT04597450
- Testing
- Lu AG06466
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Substance Use Disorders, PTSD
A Mobile App for Peer-led Seeking Safety
Peer support is historically prominent for substance use disorder (SUD), such as the world-wide model of Alcoholics Anonymous and other 12-step groups.
- Conditions
- Substance Use Disorders, PTSD, Trauma, Emotional Dysfunction
- Trial name
- NCT03846115
- Testing
- Peer-Led Seeking Safety app, Control app
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Treatment Innovations
PTSD
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD).
- Trial name
- NCT01339689
- Testing
- Ganaxolone
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Marinus Pharmaceuticals
PTSD, Anxiety
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy…
- Conditions
- PTSD, Anxiety, Anxiety Disorders, Depression
- Trial name
- EMPOWER (NCT04965740)
- Testing
- Cannabis
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Empower Research Inc
Post-Traumatic Stress Disorder (PTSD)
The PRISM Pilot Trial for Post-Traumatic Stress Disorder
A Prospective, Single-Arm, Open-Label Pilot Trial, to Assess Safety and Effectiveness of Process-Instructed Self neuro-Modulation ("Prism"), as an Adjunct to Standard of Care, in Subjects with Post-Traumatic Stress Disorder (PTSD)
- Trial name
- NCT04891614
- Testing
- PRISM
- Where
- 5 sites in United States, Israel
- Volunteers
- 87 people
- Sponsor
- GrayMatters Health Ltd.